News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
23,024 Results
Type
Article (1058)
Company Profile (2)
Press Release (21964)
Section
Business (11472)
Career Advice (49)
Deals (1448)
Drug Development (1834)
FDA (351)
Job Trends (455)
News (14459)
Policy (608)
Tag
Academia (28)
Accelerated approval (1)
Allergies (17)
Alliances (674)
ALS (3)
Alzheimer's disease (19)
Antibody-drug conjugate (ADC) (8)
Approvals (366)
Artificial intelligence (4)
Autoimmune disease (10)
Bankruptcy (10)
Best Places to Work (374)
Biosimilars (2)
Biotechnology (2)
Bladder cancer (7)
Brain cancer (2)
Breast cancer (20)
Cancer (135)
Cardiovascular disease (17)
Career advice (32)
Career pathing (2)
CAR-T (8)
Cell therapy (22)
Clinical research (1738)
Collaboration (23)
Compensation (13)
Complete response letters (4)
COVID-19 (39)
CRISPR (3)
C-suite (2)
Cystic fibrosis (7)
Data (222)
Depression (4)
Dermatology (1)
Diabetes (11)
Diagnostics (204)
Digital health (1)
Drug discovery (4)
Drug pricing (1)
Duchenne muscular dystrophy (5)
Earnings (11422)
Editorial (1)
Events (1937)
Executive appointments (4)
FDA (512)
Frontotemporal dementia (1)
Funding (11)
Gene editing (4)
Generative AI (1)
Gene therapy (13)
GLP-1 (16)
Government (51)
Grass and pollen (2)
Guidances (119)
Healthcare (540)
HIV (4)
Huntington's disease (1)
IgA nephropathy (2)
Immunology and inflammation (4)
Immuno-oncology (1)
Indications (6)
Infectious disease (45)
Inflammatory bowel disease (1)
Influenza (4)
Intellectual property (5)
Interviews (10)
IPO (1100)
Job creations (103)
Job search strategy (30)
JPM (1)
Labor market (2)
Layoffs (12)
Leadership (1)
Legal (157)
Liver cancer (2)
Lung cancer (22)
Lymphoma (19)
Machine learning (1)
Manufacturing (11)
MASH (8)
Medical device (533)
Medtech (540)
Mergers & acquisitions (352)
Metabolic disorders (26)
mRNA (3)
Multiple sclerosis (5)
Neurodegenerative disease (3)
Neuropsychiatric disorders (2)
Neuroscience (45)
NextGen: Class of 2026 (117)
Non-profit (45)
Obesity (7)
Opinion (1)
Ovarian cancer (4)
Pain (6)
Pancreatic cancer (2)
Parkinson's disease (5)
Patents (5)
Patient recruitment (7)
Peanut (4)
People (620)
Pharmacy benefit managers (1)
Phase 1 (431)
Phase 2 (700)
Phase 3 (697)
Pipeline (679)
Postmarket research (73)
Preclinical (123)
Prostate cancer (4)
Radiopharmaceuticals (11)
Rare diseases (24)
Real estate (81)
Regulatory (466)
Reports (3)
Research institute (25)
Resumes & cover letters (10)
Rett syndrome (1)
RSV (1)
Schizophrenia (5)
Series B (1)
Special edition (1)
Spinal muscular atrophy (1)
Startups (57)
Stomach cancer (1)
Vaccines (17)
Weight loss (5)
Women's health (1)
Worklife (2)
Date
Last 7 days (25)
Last 30 days (131)
Last 365 days (1254)
2026 (351)
2025 (1232)
2024 (1373)
2023 (1578)
2022 (1901)
2021 (1926)
2020 (1494)
2019 (1036)
2018 (871)
2017 (676)
2016 (361)
2015 (588)
2014 (393)
2013 (6234)
2012 (311)
2011 (358)
2010 (416)
Location
Africa (15)
Alabama (4)
Arizona (11)
Asia (1421)
Australia (157)
California (487)
Canada (159)
China (34)
Colorado (29)
Connecticut (31)
Delaware (12)
Europe (3291)
Florida (79)
Georgia (23)
Illinois (30)
India (2)
Indiana (20)
Japan (10)
Kansas (1)
Kentucky (3)
Louisiana (7)
Maine (4)
Maryland (65)
Massachusetts (288)
Michigan (16)
Minnesota (27)
Missouri (3)
Montana (1)
Nevada (3)
New Hampshire (4)
New Jersey (159)
New York (120)
North Carolina (76)
Northern California (236)
Ohio (9)
Pennsylvania (102)
South America (36)
South Carolina (1)
Southern California (211)
Tennessee (5)
Texas (48)
United States (1715)
Utah (26)
Virginia (2)
Washington State (42)
Wisconsin (5)
23,024 Results for "143".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Intelligent Bio Solutions Receives Non-Dilutive Grant Funding of USD $1.43 Million
Intelligent Bio Solutions Inc. today announced it has received a second progress payment of USD $1.43 million as part of a scientific grant awarded to the Company in 2021 for USD $4.7 million, as announced by the Company on July 8, 2021.
June 20, 2023
·
3 min read
Press Releases
AmacaThera Announces Phase 1 Results of First-in-Human Study with AMT-143, Exceeding Expectations and Paving the Way for a Novel Approach to Post-Operative Pain Relief
November 20, 2024
·
3 min read
Biotech Bay
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR) October 13-16, 2023, in Vancouver, British Columbia.
October 9, 2023
·
7 min read
HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies
HMNC Brain Health, a clinical stage biopharma company pioneering precision psychiatry, announced it has raised an additional EUR 14.3 million in a funding series, bringing the total capital raised to date to EUR 42.3 million.
October 20, 2022
·
4 min read
Business
Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA
Merck announced that it will be laying off 143 people from the Cambridge, Massachusetts-based Acceleron.
March 30, 2022
·
3 min read
·
Mark Terry
Deals
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock.
August 25, 2022
·
2 min read
BioMidwest
CinCor Pharma Raises $143 Million in Series B Financing
CinCor Pharma, Inc. (“CinCor”) today announced the completion of a $143 million Series B financing.
October 12, 2021
·
4 min read
Biotech Bay
Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share
Catalyst Biosciences, Inc. announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock previously disclosed by the Company will be September 21, 2022.
September 1, 2022
·
2 min read
Drug Development
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc announced positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study demonstrating that, as of a May 24, 2024 data cut-off date, treatment with setrusumab continued to significantly reduce incidence of fractures in patients with OI with at least 14 months of follow-up.
June 11, 2024
·
14 min read
Drug Development
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the first patients have been dosed in both of its late-stage clinical trials evaluating setrusumab in pediatric and young adult patients with OI sub-types I, III and IV.
July 6, 2023
·
8 min read
Previous
2 of 2,303
Next
